Home › Companies › SGMT

Sagimet Biosciences Inc.

SGMT Lead: Phase 3 2 Biotech Distilled articles ↓

Dermatology Metabolic Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (5 active programs)

denifanstat

resmetirom · TVB-2640

Small Molecule Target: FASN, THR-β

Metabolic Dysfunction-Associated Steatohepatitis Phase 1 oral

denifanstat

TVB-2640 · ASC40

Small Molecule Target: FASN

Acne Vulgaris Phase 3 oral Ascletis BioScience Co. Ltd.

TVB-3567

Small Molecule Target: FASN

Acne Vulgaris Phase 1 oral

denifanstat

Small Molecule Target: FASN

Acne Phase 3
Undisclosed indication oral

Biotech Distilled coverage (2)

2026-04-28 UPDATE: Sagimet Biosciences (SGMT) - The Pivot, The Raise, and the Hair-Thinning Paradox 🔒 Paid
2026-03-13 Sagimet Biosciences (SGMT) - Scientific Deep Dive for Denifanstat and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.